Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Sunshine Biopharma (SBFM) over the last 14 years, with Q3 2025 value amounting to $9.3 million.

  • Sunshine Biopharma's Cash & Current Investments fell 2375.93% to $9.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 million, marking a year-over-year decrease of 2375.93%. This contributed to the annual value of $9.7 million for FY2024, which is 4054.55% down from last year.
  • Sunshine Biopharma's Cash & Current Investments amounted to $9.3 million in Q3 2025, which was down 2375.93% from $10.3 million recorded in Q2 2025.
  • Sunshine Biopharma's Cash & Current Investments' 5-year high stood at $41.7 million during Q2 2022, with a 5-year trough of $1.7 million in Q2 2021.
  • In the last 5 years, Sunshine Biopharma's Cash & Current Investments had a median value of $12.2 million in 2024 and averaged $14.6 million.
  • In the last 5 years, Sunshine Biopharma's Cash & Current Investments skyrocketed by 970642.46% in 2021 and then tumbled by 5353.92% in 2023.
  • Sunshine Biopharma's Cash & Current Investments (Quarter) stood at $2.1 million in 2021, then skyrocketed by 963.27% to $21.8 million in 2022, then decreased by 25.35% to $16.3 million in 2023, then tumbled by 40.55% to $9.7 million in 2024, then fell by 3.92% to $9.3 million in 2025.
  • Its Cash & Current Investments stands at $9.3 million for Q3 2025, versus $10.3 million for Q2 2025 and $8.2 million for Q1 2025.